Philips launches heart studies: what it means for Philips stock
Published on 10/17/2026 at 10:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResearch and oral care developments
- Royal Philips announced the EXIT-CVD project on October 15, 2026.
- The cardiovascular consortium includes 42 partners across 17 countries and plans 22 studies.
- Philips announced a 12-member oral-care advisory board on October 8, 2026.
Royal Philips announced the launch of the five-year EXIT-CVD cardiovascular research project on October 15, 2026, according to GlobeNewswire. The project is co-funded by the European Union Innovative Health Initiative and industry partners.
Market context: Market report AEX.
The week in figures
The EXIT-CVD consortium comprises 42 public and private partners across 17 countries and plans 22 clinical studies involving more than 14,000 patients. Enrollment for the first study is scheduled to begin in October 2026. The project has a total budget of EUR 27.6 million, according to GlobeNewswire.
Chronology of the week
On October 15, 2026, Royal Philips announced EXIT-CVD, which will focus on early detection, personalized risk assessment and advanced therapies across the cardiovascular care journey. On October 8, 2026, Royal Philips announced the formation of the Philips Sonicare Global Clinical Advisory Board. The announcement, distributed through FT Company Announcements, said the board includes 12 dental experts.
Weekend trading
The Lang & Schwarz page for Philips showed a dormant quote record dated October 16, 2026. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Philips stock.
Dates of the coming week
Philips’ investor-relations page identifies the company’s second-quarter 2026 results publication as July 28, 2026. The page also lists Philips’ October 8, 2026 oral-healthcare advisory-board release among its press releases.
